Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%

MT Newswires Live07-01 10:01

Mesoblast (ASX:MSB) received a biologics license application (BLA) filing number from the US Food and Drug Administration (FDA) for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.

BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.

The company also requested a modular review of its BLA for the therapy, the filing said.

Shares rose 3% in morning trade on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648259980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648259980","market":"sh","top_or_hot":-1,"title":"Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) received a biologics license application (BLA) filing number from the US Food and Drug Administration (FDA) for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.</p><p>BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.</p><p>The company also requested a modular review of its BLA for the therapy, the filing said.</p><p>Shares rose 3% in morning trade on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-01 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) received a biologics license application (BLA) filing number from the US Food and Drug Administration (FDA) for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.</p><p>BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.</p><p>The company also requested a modular review of its BLA for the therapy, the filing said.</p><p>Shares rose 3% in morning trade on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648259980","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648259980","pubTimestamp":1782871305,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  received a biologics license application  filing number from the US Food and Drug Administration  for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.The company also requested a modular review of its BLA for the therapy, the filing said.Shares rose 3% in morning trade on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","MSB.AU":"MESOBLAST LTD","BK7501":"新冠治疗股","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","BLA.AU":"Blue Sky Alternative Inv","BK4588":"碎股","BK4585":"ETF&股票定投概念","MESO":"Mesoblast Limited"},"translate_title":"Mesoblast获得美国FDA生物制品许可申请备案号；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLA.AU":1,"MESO":1.5,"MSB.AU":1,"LABU":1.5},"content_text":"Mesoblast (ASX:MSB) received a biologics license application (BLA) filing number from the US Food and Drug Administration (FDA) for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.The company also requested a modular review of its BLA for the therapy, the filing said.Shares rose 3% in morning trade on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648259980","isCrawlerRequest":true}